These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 9670040)

  • 1. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand.
    Overwijk WW; Tsung A; Irvine KR; Parkhurst MR; Goletz TJ; Tsung K; Carroll MW; Liu C; Moss B; Rosenberg SA; Restifo NP
    J Exp Med; 1998 Jul; 188(2):277-86. PubMed ID: 9670040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100.
    Zhai Y; Yang JC; Spiess P; Nishimura MI; Overwijk WW; Roberts B; Restifo NP; Rosenberg SA
    J Immunother; 1997 Jan; 20(1):15-25. PubMed ID: 9101410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance.
    Yu Z; Theoret MR; Touloukian CE; Surman DR; Garman SC; Feigenbaum L; Baxter TK; Baker BM; Restifo NP
    J Clin Invest; 2004 Aug; 114(4):551-9. PubMed ID: 15314692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
    Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL
    Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HLA-A2.1/K(b) transgenic murine dendritic cells transduced with an adenovirus encoding human gp100 process the same A2.1-restricted peptide epitopes as human antigen-presenting cells and elicit A2.1-restricted peptide-specific CTL.
    Yang S; Linette GP; Longerich S; Roberts BL; Haluska FG
    Cell Immunol; 2000 Aug; 204(1):29-37. PubMed ID: 11006015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.
    Overwijk WW; Theoret MR; Finkelstein SE; Surman DR; de Jong LA; Vyth-Dreese FA; Dellemijn TA; Antony PA; Spiess PJ; Palmer DC; Heimann DM; Klebanoff CA; Yu Z; Hwang LN; Feigenbaum L; Kruisbeek AM; Rosenberg SA; Restifo NP
    J Exp Med; 2003 Aug; 198(4):569-80. PubMed ID: 12925674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100.
    Skipper JC; Kittlesen DJ; Hendrickson RC; Deacon DD; Harthun NL; Wagner SN; Hunt DF; Engelhard VH; Slingluff CL
    J Immunol; 1996 Dec; 157(11):5027-33. PubMed ID: 8943411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen.
    Gold JS; Ferrone CR; Guevara-Patiño JA; Hawkins WG; Dyall R; Engelhorn ME; Wolchok JD; Lewis JJ; Houghton AN
    J Immunol; 2003 May; 170(10):5188-94. PubMed ID: 12734366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An autologous oral DNA vaccine protects against murine melanoma.
    Xiang R; Lode HN; Chao TH; Ruehlmann JM; Dolman CS; Rodriguez F; Whitton JL; Overwijk WW; Restifo NP; Reisfeld RA
    Proc Natl Acad Sci U S A; 2000 May; 97(10):5492-7. PubMed ID: 10779556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.
    Overwijk WW; Lee DS; Surman DR; Irvine KR; Touloukian CE; Chan CC; Carroll MW; Moss B; Rosenberg SA; Restifo NP
    Proc Natl Acad Sci U S A; 1999 Mar; 96(6):2982-7. PubMed ID: 10077623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.
    Zhai Y; Yang JC; Kawakami Y; Spiess P; Wadsworth SC; Cardoza LM; Couture LA; Smith AE; Rosenberg SA
    J Immunol; 1996 Jan; 156(2):700-10. PubMed ID: 8543823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
    Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
    Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells.
    Nagorsen D; Panelli M; Dudley ME; Finkelstein SE; Rosenberg SA; Marincola FM
    Gene Ther; 2003 Sep; 10(20):1754-65. PubMed ID: 12939642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC class I and class II epitopes from the melanoma antigen glycoprotein 100.
    Lapointe R; Royal RE; Reeves ME; Altomare I; Robbins PF; Hwu P
    J Immunol; 2001 Oct; 167(8):4758-64. PubMed ID: 11591807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stimulation of tumor-reactive T lymphocytes using mixtures of synthetic peptides derived from tumor-associated antigens with diverse MHC binding affinities.
    Riley JP; Rosenberg SA; Parkhurst MR
    J Immunol Methods; 2003 May; 276(1-2):103-19. PubMed ID: 12738363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma.
    Rosenberg SA; Yang JC; Schwartzentruber DJ; Hwu P; Topalian SL; Sherry RM; Restifo NP; Wunderlich JR; Seipp CA; Rogers-Freezer L; Morton KE; Mavroukakis SA; Gritz L; Panicali DL; White DE
    Clin Cancer Res; 2003 Aug; 9(8):2973-80. PubMed ID: 12912944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Manipulation of avidity to improve effectiveness of adoptively transferred CD8(+) T cells for melanoma immunotherapy in human MHC class I-transgenic mice.
    Bullock TN; Mullins DW; Colella TA; Engelhard VH
    J Immunol; 2001 Nov; 167(10):5824-31. PubMed ID: 11698456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.
    Morgan RA; Dudley ME; Yu YY; Zheng Z; Robbins PF; Theoret MR; Wunderlich JR; Hughes MS; Restifo NP; Rosenberg SA
    J Immunol; 2003 Sep; 171(6):3287-95. PubMed ID: 12960359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.
    Kawakami Y; Eliyahu S; Jennings C; Sakaguchi K; Kang X; Southwood S; Robbins PF; Sette A; Appella E; Rosenberg SA
    J Immunol; 1995 Apr; 154(8):3961-8. PubMed ID: 7706734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of circulating tumor-reactive CD8+ T cells after vaccination of melanoma patients with the gp100 209-2M peptide.
    Meijer SL; Dols A; Jensen SM; Hu HM; Miller W; Walker E; Romero P; Fox BA; Urba WJ
    J Immunother; 2007; 30(5):533-43. PubMed ID: 17589294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.